Related Experiment Video
Updated: Jan 9, 2026
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Treatment Patterns in Patients With Incident Pulmonary Hypertension: Real-World Data From the Pulmonary Hypertension
Sarah L Khan1, Carly J Paoli2, Noah Kime3
1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
Background:
Current evidence supports risk-based treatment for pulmonary arterial hypertension (PAH) with an endothelin receptor antagonist and phosphodiesterase type 5 inhibitor as initial therapy for patients with low- and intermediate-risk PAH, and triple therapy with the addition of a parenteral prostacyclin for patients with high-risk PAH.
Research Question:
What are the current treatment patterns for patients with newly diagnosed PAH in the Pulmonary Hypertension Association Registry (PHAR)?
Study Design And Methods:
This analysis was performed in a prospectively collected cohort of patients with incident PAH diagnosed by right heart catheterization and enrolled in the PHAR between September 30, 2015, and February 14, 2024. The primary objective was to assess the guideline-recommended risk-based treatment approaches and their impact in the real world. All-cause mortality was compared across risk groups and between patients receiving monotherapy, dual therapy, and triple therapy for PAH across risk strata.
Results:
There were 1,019 patients with incident PAH in the PHAR who received either initial monotherapy (n = 344, 33.8%), dual therapy (n = 557, 54.7%), or triple therapy (n = 118, 11.6%). Of 323 patients with complete data for risk classification who received initial monotherapy, 25.1% were low risk, 31.3% were intermediate risk, and 43.7% were high risk by Registry to Evaluate Early and Long-term PAH Disease Management Lite 2 risk score. For the 540 patients treated with initial dual therapy, 35.7% were low risk, 26.5% were intermediate risk, and 37.8% were high risk. Finally, among the 113 patients who received initial triple therapy, 31.9% were low risk, 28.3% were intermediate risk, and 39.8% were high risk. All-cause mortality was lowest for patients with low-risk PAH at baseline and highest for those with high-risk PAH at baseline across the entire cohort and for patients treated with initial monotherapy, dual therapy, or triple therapy.
Interpretation:
This analysis highlights the underutilization of PAH therapies for patients with newly diagnosed PAH in this real-world patient population.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...